Gonadotropin releasing hormone agonist therapy and its effect on bone mass

T Nencioni, M Penotti, M Barbieri-Carones, S Ortolani, C Trevisan, F Polvani
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 1991 · vol. 5(1) , pp. 49–56 · doi:10.3109/09513599109049941 · PMID:1910246 · W2136328742
article OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

Six months of gonadotropin releasing hormone agonist therapy in patients with endometriosis or uterine fibroids significantly decreased bone mineral density at both lumbar spine and forearm sites.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The effects on bone mass of a 6 month therapeutic cycle with a gonadotropin releasing hormone agonist (GnRHa) were studied in 22 patients, ten affected by pelvic endometriosis and 12 by uterine fibroids.All patients were subjected to preliminary full examinations to confirm their diagnosis (laparoscopy for the endometriosis group and precise ultrasound volume measurements for uterine fibroids group). Before the beginning of treatment, bone mineral density (BMD) was measured in each patient both on the distal third of the forearm, with single-photon absorptiometry, and on the lumbar spine (L1–L4), with dual photon absorptiometry.The gonadotropin releasing hormone agonist used was buserelin. In the first week of therapy 0.5 mg of the drug was administered subcutaneously thrice daily. In the following 25 weeks the same drug was given intranasally, at a dosage of 300 μg again three times a day. Bone mass measurements, both at the peripheral and at the axial site, were repeated at the end of the 26-week therapeutic cycle and then again 6 months later.At the 26th week, a significant decrease of BMD was observed at both sites. The loss was 1.5% (p < 0.05) on the lumbar spine, and 2.1% (p < 0.05) on the radius. No bone mass restoration took place in the following 6 months. On the contrary, a less significant but discernible trend towards a further bone loss was apparent in the BMD values measured 6 months after the end of therapy. Comparing these values with those obtained at the beginning of therapy, the observed loss comes out as approximately 3% at both sites @ < 0.01 for the lumbar spine measurements and p < 0.05 for the forearm ones).These results show the need to take this relevant side-effect into serious account when administering GnR Has to patients, and suggest the opportunity of developing a therapeutic supplement to prevent or lessen it.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Bone Density Buserelin Adult Amenorrhea Amenorrhea Bone Density Buserelin Buserelin Endometriosis Endometriosis Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Luteinizing Hormone Luteinizing Hormone Middle Aged Time Factors

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (14)

Cited by (10)

Source provenance

europepmc
last seen: 2026-06-22T06:15:23.361955+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:00.397535+00:00
License: CC0 · commercial use OK